NASH failures only add to ultimate prize, analyst says

9 August 2023

The prevalence of non-alcoholic steatohepatitis (NASH), a more advanced stage of nonalcoholic fatty liver disease, continues to increase.

Intercept Pharmaceuticals (Nasdaq: ICPT) has joined the list of companies which have failed in their attempts to be the first to enter the NASH market. The biopharma company received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for its farnesoid X receptor agonist, obeticholic acid (OCA).

With the wait for an FDA-approved therapy continuing, the NASH market holds enormous untapped potential, according to the data and analytics company GlobalData.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK